Experience with emetine hydrochloride (NSC 33669) as an antitumor agent.
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D003967:Diarrhea / Q000139:chemically induced; D004562:Electrocardiography; D004640:Emetine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D009220:Myositis / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D013610:Tachycardia / Q000139:chemically induced; D013964:Thyroid Neoplasms / Q000188:drug therapy; D014134:Tracheal Neoplasms / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D004640:Emetine